Table 2 Anticoagulant use outcomes in the study period
IMS | MarketScan Commercial | MarketScan Medicare | Optum | Medicaid | |
|---|---|---|---|---|---|
All patients, N | 30,757 | 21,976 | 38,643 | 9,120 | 4,901 |
Patients receiving anticoagulant by stroke risk* and age category, N (%) | |||||
All Stroke Risk Levels | 11,382 (37%) | 6,444 (29%) | 14,686 (38%) | 3,595 (39%) | 803 (16%) |
High Risk | 6,832 (43%) | 1,934 (39%) | 9,822 (40%) | 1,946 (51%) | 566 (19%) |
Age <65 years | 1,252 | 1,877 | 58 | 672 | 476 |
Age: 65–74 years | 1,484 | 57 | 1,651 | 386 | 38 |
Age ≥ 75 years | 4,090 | 0 | 8,113 | 888 | 52 |
Moderate Risk | 3,130 (34%) | 2,415 (31%) | 3,788 (36%) | 1,091 (36%) | 172 (13%) |
Age <65 years | 1,149 | 2,311 | 34 | 696 | 158 |
Age: 65–74 years | 1,213 | 104 | 1,600 | 292 | 11 |
Age ≥ 75 years | 764 | 0 | 2,154 | 103 | 3 |
Low Risk | 1,420 (25%) | 2,095 (23%) | 1,076 (33%) | 558 (25%) | 65 (12%) |
Age <65 years | 813 | 1,940 | 12 | 423 | 63 |
Age: 65–74 years | 603 | 155 | 1,064 | 135 | 2 |
Age ≥ 75 years | 0 | 0 | 0 | 0 | 0 |
Anticoagulant MPR | |||||
MPR | 0.58 | 0.58 | 0.66 | 0.61 | 0.72 |
Gap in Anticoagulation Therapy | |||||
Patients with a Gap in Anticoagulation Therapy, N(%) | 6,745 (59%) | 3,828 (59%) | 6,687 (46%) | 1,883 (52%) | 233 (29%) |
Average Time to First Gap in Anticoagulation Therapy (days) | 132 | 150 | 157 | 144 | 129 |